Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-cash Items (2018 - 2025)

Historic Non-cash Items for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Q2 2025 value amounting to $81.3 million.

  • Crinetics Pharmaceuticals' Non-cash Items fell 7187.51% to $81.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $81.3 million, marking a year-over-year decrease of 7187.51%. This contributed to the annual value of $337.7 million for FY2024, which is 6087.55% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Non-cash Items of $81.3 million as of Q2 2025, which was down 7187.51% from $7.0 million recorded in Q1 2025.
  • Crinetics Pharmaceuticals' Non-cash Items' 5-year high stood at $3.0 billion during Q4 2021, with a 5-year trough of $2172.0 in Q1 2021.
  • Its 5-year average for Non-cash Items is $250.5 million, with a median of $15.1 million in 2022.
  • The largest annual percentage gain for Crinetics Pharmaceuticals' Non-cash Items in the last 5 years was 15265280.0% (2021), contrasted with its biggest fall of 9999.21% (2021).
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Non-cash Items stood at $3.0 billion in 2021, then crashed by 99.23% to $23.1 million in 2022, then soared by 806.67% to $209.9 million in 2023, then soared by 60.88% to $337.7 million in 2024, then tumbled by 75.93% to $81.3 million in 2025.
  • Its last three reported values are $81.3 million in Q2 2025, $7.0 million for Q1 2025, and $337.7 million during Q4 2024.